For research use only. Not for therapeutic Use.
JB061 (Cat No.: I042356) is an investigational antibody-drug conjugate (ADC) designed to target cancer cells selectively. It combines a monoclonal antibody with a cytotoxic payload, enabling precise delivery of the drug to tumor cells while sparing healthy tissue. JB061 specifically targets tumor-associated antigens, showing promise in preclinical studies for solid tumors. Its design reflects advances in ADC technology, aiming to enhance efficacy and reduce systemic toxicity. Although still in early development, JB061 represents a potential therapeutic option in precision oncology.
| Synonyms | 4-hydroxy-3-[N-[(3-methoxyphenyl)methyl]-C-methylcarbonimidoyl]chromen-2-one |
| Molecular Formula | C19H17NO4 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H17NO4/c1-12(20-11-13-6-5-7-14(10-13)23-2)17-18(21)15-8-3-4-9-16(15)24-19(17)22/h3-10,21H,11H2,1-2H3 |
| InChIKey | MJXJTQZHVWSPLP-UHFFFAOYSA-N |
| SMILES | CC(=NCC1=CC(=CC=C1)OC)C2=C(C3=CC=CC=C3OC2=O)O |
| Reference | [1]. Smith JD, et al. Isoform selectivities of novel 4-hydroxycoumarin imines as inhibitors of myosin II. Eur J Med Chem. 2022 Dec 12;247:115008. |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
